RFG Advisory LLC Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

RFG Advisory LLC purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 14,941 shares of the company’s stock, valued at approximately $888,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Federated Hermes Inc. lifted its holdings in Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after buying an additional 339 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in Tarsus Pharmaceuticals by 6.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,626 shares of the company’s stock worth $349,000 after acquiring an additional 505 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Tarsus Pharmaceuticals by 9.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 8,438 shares of the company’s stock valued at $342,000 after acquiring an additional 740 shares during the period. Franklin Resources Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 3.6% during the second quarter. Franklin Resources Inc. now owns 21,402 shares of the company’s stock valued at $867,000 after purchasing an additional 750 shares during the last quarter. Finally, Profund Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 12.7% during the 2nd quarter. Profund Advisors LLC now owns 9,469 shares of the company’s stock worth $384,000 after purchasing an additional 1,064 shares during the period. 90.01% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the transaction, the insider owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 3.3%

Tarsus Pharmaceuticals stock opened at $63.25 on Friday. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -31.31, a price-to-earnings-growth ratio of 0.94 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The firm’s 50 day moving average price is $74.70 and its two-hundred day moving average price is $66.69. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. HC Wainwright boosted their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $82.29.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.